Peters S Zimmermann S 2014 HER2 mutations, largely exon 20 in-frame insertions, have been described as an oncogenic driver alteration in 1% to 4% of NSCLC, exclusively in adenocarcinoma histology. The prognostic implication of these alterations is not known. Phase I and II trial data suggest that afatinib, neratinib and dacomitinib have some activity in this molecular subgroup. No comparative data, or any data regarding the activity of pertuzumab or trastuzumab-emtansine is available. HER2 deregulation either by protein overexpression or gene amplification, has little clinical relevance to date, as trials investigating trastuzumab activity merely suggest a benefit in the very small minority of patients whose tumor highly overexpresses HER2, a subpopulation that amounts to 2% to 6% of mostly adenocarcinomas. https://sonar.ch/global/documents/546 eng info:eu-repo/semantics/altIdentifier/doi/10.3978/j.issn.2218-6751.2014.02.06 info:eu-repo/semantics/altIdentifier/pmid/25806285 Translational lung cancer research. - 2014 HER2 mutations afatinib dacomitinib irreversible pan HER-receptor inhibitor lung cancer Targeted therapy in NSCLC driven by HER2 insertions. http://purl.org/coar/resource_type/c_6501